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Abstract. The efficacy and safety of hydroxychloroquine (HCQ) for the prevention and treatment of COVID-19 has
received great attention, and most notably, the enthusiasm for HCQ has been one of politicization rather than science.
Laboratory studies andcaseseriespublishedearly in thepandemic supported its efficacy. Thescientificcommunity raced
to conduct observational and randomized evaluations of the drug in all stages of the disease, including prophylaxis, early
treatment, and advanced disease. Yet a divisive media response affected recruitment, funding, and subsequent en-
thusiasm for continuing scientific investigations.Of themore than300HCQtrials registered, fewer than50%report having
recruited any patients, and most trials might fail to achieve any useful portions of their intended sample size. Multiple
observational studies and two large randomized trials have demonstrated HCQdoes not offer efficacy against COVID-19
in hospitalized patients. Prophylaxis studies and early treatment studies provided heterogeneous results and are plagued
by low event rates and poor study outcome monitoring. Emerging high-quality evaluations of prophylaxis and early
treatment do not support a role for HCQ in these populations. The story of HCQ for COVID-19 has followed a pattern of
initial enthusiasm supported by poor quality evidence, followed by disappointment based on more rigorous evaluations.
The experience of HCQ in the COVID-19 era calls for the depoliticization of science away from media glare.
The SARS-CoV-2 (COVID-19) pandemic has ushered un-
precedented global collaboration by clinical scientists to
identify candidate therapeutics for the treatment ofCOVID-19.
Efforts rapidly identified effective therapies against advanced
COVID-19, including remdesivir,1 shown to reduce the dura-
tion of hospitalization, and dexamethasone,2 shown to reduce
mortality among severely sick patients. But in this global effort
to identify effective therapies against COVID-19, no drug has
been scrutinized nor generated more scientific and political
commentary, than hydroxychloroquine (HCQ). The aim of this
commentary was to provide a narrative of the political and
scientific story of HCQ in the COVID-19 pandemic era to un-
derstand how the drug became so contentious in the public,
political, and scientific arenas.
In early 2020, as the COVID-19 pandemic spread, the ur-
gency to identify an effective therapy became evident.
Repurposing already existing medicines is a priority due to
their known safety profiles, availability, and ease of adminis-
trative issues. Hydroxychloroquine was identified as an early
potential therapeutic candidate, drawing on evidence from
reports of both in vitro and in vivo testing. Hydroxychloroquine
is an inexpensive and globally accessible drug listed on the
WHO’s list of Essential Medicines, approved for the treatment
of rheumatic diseases and as both a treatment and pro-
phylaxis formalaria.3 InMarch 2020, a study published by Yao
et al.4 reported findings from an in vitro study that supported a
loading dose of 400mg twice daily of HCQsulfate given orally,
followed by a maintenance dose of 200 mg given twice daily
for 4 days to treat SARS-CoV-2 infection. These findings were
then used as justification for further clinical evaluation of HCQ
as a treatment for COVID-19.
The first clinical report evaluating HCQ for the treatment
of COVID-19 was an observational study of 20 patients
treated in France with HCQ and found at day 6 post-
inclusion, 70% of HCQ-treated patients were virologically
cured compared with 12.5% in a control group (reported as
highly significant, P = 0.001). The investigators reported
that HCQ showed dramatic clinical benefit in reducing viral
load and disease symptoms.5 Many methodological issues
were noted about these initial reports, including small
sample sizes, lack of randomization, lack of inclusion cri-
teria, and overinterpretation of findings.6,7 These study
findings were then widely reported in the medical press and
by political leaders, resulting in the issuance of an emer-
gency use authorization for HCQ in the United States (US),
France, Ukraine, and Turkey, among others.8
This media attention resulted in a remarkable rise in both
the off-label use of HCQ and interest within the clinical
research community. The number of clinical trial registra-
tions that aimed to assess the efficacy and safety of HCQ
(www.covid19-trials.com) increaseddramatically. At the same
time, evidence emerged that COVID-19 is not a single disease
but represents a spectrum of disease, from prophylaxis pop-
ulations, to early treatment and hospitalized patients whomay
eventually require intensive care. The clinical research world
was inadequately aware of the disease stages and so a
plethora of trials evaluating antivirals in severe disease as well
as application of findings from hospitalized patients to am-
bulatory patients. As of October 30, 2020, there were 2,462
trials registered to evaluate interventions for COVID-19; 341 of
these trials intended to evaluate HCQ. Trial registrations for
evaluations ofHCQpeaked inApril 2020,wheremore thanhalf
of registered trials intended to recruit patients in the hospi-
talized setting (Figure 1). Although registration of a trial indi-
cates an intention to conduct study, it does not however
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necessarily confirm whether a registered trial was ever
initiated.
As trial registrations grew, observational study reports also
emerged. These findings were generated nearly exclusively
from studies among hospitalized populations, often in single
hospital settings, and reported widely heterogeneous
results.9–11 Some of these studies demonstrated a clinical
benefit for the use of HCQ/CQ, whereas others showed no
difference to placebo or standard of care.12 These observa-
tional studies also raised concern for cardiotoxic harm asso-
ciated with the use of HCQ.13 By May 2020, as published
results among hospitalized patients frompredominantly Asian
countries began to appear, it became clear that the evidence
for HCQ as a treatment of COVID-19 was inconsistent and
contradictory.14 Among the first 12 reports evaluating the ef-
ficacy of HCQ using both observational studies and clinical
trials, in a combined sample of 3,543 hospitalized patients,
there was no clear evidence to support continued use of this
drug for hospitalized patient populations.15
The narrative on HCQ/CQ importantly shifted in May 2020
when the Lancet published and then retracted a study
reporting no benefits of HCQ/CQ, after revelations surfaced
that the authors’ study conclusions were based on un-
substantiated data.16 The study alleged to report on 96,032
patients across 671 hospitals worldwide and showed an in-
creased risk of de-novo ventricular arrhythmia with treatment
with HCQ. Although retracted, the messaging about associ-
ated risk of cardiac events, specifically extendedQT intervals,
led researchers, clinicians, and trial funders to become more
skeptical of the safety and toxicity of HCQ.17 This had a dra-
matic effect on the number of new HCQ trials registrations
(Figure 1) from April 2020 onward and resulted in trial funding
abruptly ending and study ethics approvals rescinded for
some of the largest planned HCQ trials.18
In July 2020, in the UK, the Randomised Evaluation of
COVID-19 therapy (RECOVERY) trial reported results that
showed potential harmwith the use of HCQ in the treatment of
COVID-19 among hospitalized patients (risk ratio for death at
28 days, 0.92; 95% CI: 0.85–0.99).19 This report further dis-
solved much remaining enthusiasm for therapeutic effects of
HCQ in the clinical trial community evaluating hospitalized
patients. Funding for HCQ trials also became increasingly
more difficult to secure. TheWHOSolidarity trial, for example,
a multinational adaptive platform trial among hospitalized
patients with COVID-19, was temporarily placed on hold, as
was the COPCOV trial that intended to enroll forty thousand
health workers to evaluate HCQ as prophylaxis.20 Sub-
sequently, the CROWNCoronation Trial, evaluating HCQ as a
prophylactic among30,000healthworkers, switched theHCQ
arm to a measles, mumps, and rubella vaccine.21
As onemight expect, the number of registered trials and the
number of trials recruiting showed important differences. In
the first two quarters of the year, 241 HCQ or CQ trials were
registered. By July 1, 2020, only 51% of trials had begun re-
cruitment. This decline in clinical trial registrations for HCQ
evaluation continued into themonthsof July andAugust 2020.
Clinical trial registrations in hospitalized populations dropped
most substantially, but so did those in prophylaxis and out-
patient settings (Figure 1).
There are several reasons a trial may not recruit or may only
recruit a small proportion of the intended population. Chief
among these reasons are insufficient funding and an in-
sufficient supply of patients. Yet it is important to recognize
that a trial that failed to recruit its intended sample size should
not be considered a failure but rather a reason for possible
collaboration. For example, the vast majority of clinical trials
among early treatment populations in the United States were
unable to recruit because of testing delays, and so a trial that
FIGURE 1. Number of active registered trials investigating hydroxychloroquine by date amongpatient populations of prophylaxis, outpatient, and
hospitalized settings. This figure appears in color at www.ajtmh.org.
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intends to recruit, for example, 500 patients may only ever
hypothetically recruit 50 patients. However, collaboration
between 10 such trials will reach the target sample size. There
are now several initiatives to promote collaboration and
sharing of data. These include the Gates Medical Research
Institute (GMRI), the UK Workbench, and the NIH Active Col-
laboration. Specifically, the GMRI has reached out to trialists
evaluating HCQ in early treatment populations to formally
commit to sharing data regardless of the sample size
recruited, with the intention of increasing statistical power
through each additional collaboration. This is conceptually an
individual patient data meta-analysis and is likely the only
strategy that will yield findings for HCQ.
Scientificconsensushas nowemerged that there is a lackof
clinical benefit for using HCQ/CQ among hospitalized pa-
tients. Both the UK RECOVERY and the WHO SOLIDARITY
trials (rate ratio: 1.19; 95% CI: 0.89–1.59) have now reported
their findings on HCQ among hospitalized patients and failed
to detect any benefit.22 On June 25, 2020, the U.S. The Food
and Drug Administration announced it had revoked the
emergency use authorization for HCQ and CQ.23 But, while
enthusiasm for HCQ to treat COVID-19 has dwindled, there
was a rational argument for continuing investigations of HCQ
as prophylaxis or its effect in the early phase of the disease.24
Hydroxychloroquine has antiviral activity against SARS-CoV-
2 in laboratory studies through a number of direct molecular
actions and anti-inflammatory and immunomodulatory ef-
fects,25 and respected voices argued that if HCQwere to play
an important role, it would be in prophylaxis or early treatment
of the disease, when it was primarily a viral infection stage
of the disease.26 Several pre-exposure and postexposure
prophylaxis trials have now been reported. A meta-analysis
evaluating HCQ prophylaxis (both pre- and postexposure)
reported a significant pooled risk reduction of 22% (95% CI:
1–39) based on four trials.27 Although this generated enthusi-
asmagain that HCQmay have a role in this pandemic, updating
this with two new randomized controlled trials (RCTs) of pro-
phylaxis with nonsignificant findings changes the detected ef-
fect importantly (risk reduction 16%, 95% CI: −2 to 30).28
Similarly, early treatment of COVID-19 with HCQ initially
yielded disparate results. Among 10 RCTs enrolling 2,535
patients, outcomes reporting on viral clearance after an av-
erage of 7 days of treatment were largely negative for HCQ
treatment, and the number of hospitalizations reported in the
trials was only 3.6%, indicating that detecting whether HCQ
prevents disease progression in clinical trials is statistically
difficult.29 Early treatment trials in COVID-19 are particularly
challenging as we are aware that most patients, regardless of
risk profiles, will clear the virus irrespective of treatment, and
only a small numberwill progress to hospitalization and death.
In the most detailed of the early treatment trials with regard to
viral monitoring. This study was terminated early for futility of
clinical endpoints. The largest RCT using hospitalization as an
outcome, from Brazil, found no effect of HCQ on hospitali-
zations or death and was similarly terminated because of fu-
tility (risk ratio: 1.00; 95% CI: 0.45–2.21, unpublished).
The story ofHCQclinical trials hasbeen influenced strongly,
by political endorsements, media scrutiny with a political
agenda, anda lackof rigorous scientificdebate.31Widespread
anxieties have been fueled by results being retracted in a
scientific arena where information has become overtly politi-
cized. Although we hope medicine can be apolitical, the
trajectory of media interest in HCQ and its promotion by pol-
iticians has dramatically affected the funding, conduct, and
interpretation of clinical trials.17 It is almost always the case
that research priorities in medicine are determined through a
combination of financial, political, and social factors; what is
distinctive in this case is that both research priorities and re-
search findings have been swayed by these elements.
Emerging evidence suggests that the scientific and political
storyofHCQhasbeenoneofariseandfall—initialenthusiasmand
scientific signals supported by low-quality evidence, followed by
subsequent disappointment and lack of statistical effects asmore
rigorous evaluations are reported. The story of HCQ and COVID-
19 is an important one to document. There is a clear need for
clinical trials to explore promising, scalable, and cost-efficient
therapeuticsandvaccines forCOVID-19globally, and an urgent
need to allow sound science to guide public health policy,
rather than politics or poor-quality designs.
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